NEW YORK (GenomeWeb News) – Strategic Diagnostics reported after the close of the market yesterday that its third-quarter revenues increased around 5 percent to $6.9 million from $6.6 million.
 
The Newark, Del.-based antibody and proteomics research products firm said that its third-quarter revenues were positively impacted by a 38 percent increase in sales of food pathogen products, a 14 percent increase in sales of water and environmental products, and a 191 percent rise in genomic antibody technology sales.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.